Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders

Jeffrey A. Cohen, Jonathan L. Carter, R. Philip Kinkel, Steven R. Schwid

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

There is increasing impetus to begin disease-modifying therapy for relapsing multiple (R-MS) early, before the development of irreversible tissue damage and resultant permanent disability. However, all of the currently-approved therapies for relapsing multiple sclerosis are only partially effective for patients as a group. Treatment failure can be due to noncompliance with therapy, intolerable adverse effects, the development of neutralizing antibodies, or non-responsive disease. Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)29-36
Number of pages8
JournalJournal of Neuroimmunology
Volume98
Issue number1
DOIs
StatePublished - Jul 1 1999

Fingerprint

Multiple Sclerosis
Therapeutics
Neutralizing Antibodies
Treatment Failure

Keywords

  • Adverse effects
  • Combination therapy
  • Compliance
  • Magnetic resonance imaging
  • Neutralizing antibodies
  • Treatment failure

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. / Cohen, Jeffrey A.; Carter, Jonathan L.; Kinkel, R. Philip; Schwid, Steven R.

In: Journal of Neuroimmunology, Vol. 98, No. 1, 01.07.1999, p. 29-36.

Research output: Contribution to journalArticle

Cohen, Jeffrey A. ; Carter, Jonathan L. ; Kinkel, R. Philip ; Schwid, Steven R. / Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. In: Journal of Neuroimmunology. 1999 ; Vol. 98, No. 1. pp. 29-36.
@article{9b28f882de204584bb3fc278a97c8639,
title = "Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders",
abstract = "There is increasing impetus to begin disease-modifying therapy for relapsing multiple (R-MS) early, before the development of irreversible tissue damage and resultant permanent disability. However, all of the currently-approved therapies for relapsing multiple sclerosis are only partially effective for patients as a group. Treatment failure can be due to noncompliance with therapy, intolerable adverse effects, the development of neutralizing antibodies, or non-responsive disease. Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary. Copyright (C) 1999 Elsevier Science B.V.",
keywords = "Adverse effects, Combination therapy, Compliance, Magnetic resonance imaging, Neutralizing antibodies, Treatment failure",
author = "Cohen, {Jeffrey A.} and Carter, {Jonathan L.} and Kinkel, {R. Philip} and Schwid, {Steven R.}",
year = "1999",
month = "7",
day = "1",
doi = "10.1016/S0165-5728(99)00078-8",
language = "English (US)",
volume = "98",
pages = "29--36",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders

AU - Cohen, Jeffrey A.

AU - Carter, Jonathan L.

AU - Kinkel, R. Philip

AU - Schwid, Steven R.

PY - 1999/7/1

Y1 - 1999/7/1

N2 - There is increasing impetus to begin disease-modifying therapy for relapsing multiple (R-MS) early, before the development of irreversible tissue damage and resultant permanent disability. However, all of the currently-approved therapies for relapsing multiple sclerosis are only partially effective for patients as a group. Treatment failure can be due to noncompliance with therapy, intolerable adverse effects, the development of neutralizing antibodies, or non-responsive disease. Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary. Copyright (C) 1999 Elsevier Science B.V.

AB - There is increasing impetus to begin disease-modifying therapy for relapsing multiple (R-MS) early, before the development of irreversible tissue damage and resultant permanent disability. However, all of the currently-approved therapies for relapsing multiple sclerosis are only partially effective for patients as a group. Treatment failure can be due to noncompliance with therapy, intolerable adverse effects, the development of neutralizing antibodies, or non-responsive disease. Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary. Copyright (C) 1999 Elsevier Science B.V.

KW - Adverse effects

KW - Combination therapy

KW - Compliance

KW - Magnetic resonance imaging

KW - Neutralizing antibodies

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=0032983729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032983729&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(99)00078-8

DO - 10.1016/S0165-5728(99)00078-8

M3 - Article

C2 - 10426359

AN - SCOPUS:0032983729

VL - 98

SP - 29

EP - 36

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1

ER -